MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 22, 2006; DOI: 10.1124/mol.106.026989


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.026989v1
70/5/1802    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blanquart, C.
Right arrow Articles by Issad, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blanquart, C.
Right arrow Articles by Issad, T.


Received for publication May 22, 2006.
Revised August 21, 2006.
Accepted for publication August 22, 2006.

Monitoring the activation state of insulin/IGF-1 hybrid receptors using Bioluminescence Resonance Energy Transfer

Christophe Blanquart 1, Carmen Gonzalez-Yanes 1, Tarik Issad 1*

1 CNRS-INSERM-Universite Rene Descartes

* Address correspondence to: E-mail: issad{at}cochin.inserm.fr

Abstract

In cells expressing both the insulin receptor isoform A (IRA) and the insulin like growth factor-1 receptor (IGF1R), the presence of hybrid receptors, constituted of an {alpha}{beta}-IRA chain associated with an {alpha}{beta}-IGF1R chain, has been demonstrated. These heterodimers are found in normal cells, and also appear to play crucial roles in a number of cancers. However, they remain difficult to study, due to the concomitant presence of IRA and IGF1R homodimers. Using bioluminescence resonance energy transfer (BRET), we have developed assays to specifically monitor the activation state of IRA/IGF1R hybrids, both in vitro and in living cells. The first assay allowed the study of ligand-induced conformational changes within hybrid receptors purified from cells co-transfected with one type of receptor fused to Renilla luciferase (Rluc) and the other type of receptor fused to yellow fluorescent protein (YFP). In these conditions, only hybrid receptors were BRET competent. In the second assay, the activation state of IRA/IGF1R hybrids was monitored in real time, in living cells, by co-transfection of kinase-dead version of IRA-Rluc or IGF1R-Rluc, wild-type untagged IRA or IGF1R, and a YFP-tagged soluble version of the substrate-trapping mutant of protein tyrosine-phosphatase 1B (YFP-PTP1B-D181A-Cter). In hybrid receptors, trans-phosphorylation of the kinase-dead {alpha}{beta}-Rluc moiety by the wild-type {alpha}{beta} moiety induced the recruitment of YFP-PTP1B-D181A-Cter, resulting in a hybrid-specific ligand-induced BRET signal. Therefore, both methods allow monitoring of the activity of IRA/IGF1R hybrid receptor and could be used to detect molecules of therapeutic interest for the treatment of cancer.


Key words: Insulin, Fluorescence techniques


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
P. K. Tan, J. Wang, P.-L. H. Littler, K. K. Wong, T. A. Sweetnam, W. Keefe, N. R. Nash, E. C. Reding, F. Piu, M. R. Brann, et al.
Monitoring Interactions between Receptor Tyrosine Kinases and Their Downstream Effector Proteins in Living Cells Using Bioluminescence Resonance Energy Transfer
Mol. Pharmacol., December 1, 2007; 72(6): 1440 - 1446.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics